Trial Profile
Phase II study of oxaliplatin based regimen in relapsed colon cancer patients treated with oxaliplatin based adjuvant
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Bevacizumab; Capecitabine; Cetuximab; Fluoropyrimidine derivatives; Fluorouracil; Folinic acid; Gimeracil/oteracil/tegafur; Panitumumab
- Indications Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- Acronyms INSPIRE
- 21 Sep 2020 Results assessing update analysis on efficacy and allergic reactions due to Ox re-introduction presented at the 45th European Society for Medical Oncology Congress
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.